Important Safety Information
      
A unique heritage in ophthalmology, a special commitment to Retina
Allergan has a heritage of nearly 60 years in discovering and developing new therapeutic agents for eye care. For the past 6 years, we have been one of the fastest-growing eye care companies worldwide.1 Eye care professionals and patients rely on Allergan products to treat a variety of eye conditions, including elevated intraocular pressure, dry eye, and external eye diseases.

Allergan Retina, a specialty unit of Allergan, extends our eye care expertise to the back of the eye. We are committed to discovering and developing innovative therapies for patients who suffer from diseases such as retinal vein occlusion and posterior segment uveitis.


Click the button below to learn about OZURDEX®:
Indications
OZURDEX® (dexamethasone intravitreal implant) is an implant injected into the eye (vitreous) and used:
  • To treat adults with macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
  • To treat adults with noninfectious uveitis affecting the posterior segment of the eye
Important Safety Information

OZURDEX® should not be used in patients who have any infections or diseases in the eye, or surrounding eye area, including most viral diseases of the cornea and conjunctiva, including active herpes viral infection of the eye, vaccinia, varicella, mycobacterial infections, and fungal diseases.

OZURDEX® should not be used in patients with advanced glaucoma. You should not use OZURDEX® if you are allergic to one of its ingredients.

Injections into the vitreous in the eye are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.

Use of corticosteroids may produce posterior subcapsular cataracts, increased eye pressure, glaucoma, and may increase the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

In the days following injection with OZURDEX®, patients are at risk for potential complications including in particular, but not limited to, the development of serious eye infection or elevated intraocular pressure. If your eye becomes red, sensitive to light, painful, or develops a change in vision, you should seek immediate care from your eye doctor. You may experience temporary visual blurring after receiving an injection and should not drive or use machines until this has resolved.

The most common side effects reported in patients include: increased eye pressure, conjunctival bleeding, eye pain, conjunctival hyperemia, ocular hypertension, cataract, vitreous detachment, and headache.

OZURDEX® is for prescription use only. Individual results with OZURDEX® may vary.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full prescribing information. Click here.

Reference:

  1. Intercontinental Medical Statistics (IMS): 48 countries roll up. MAT Q2 2007, excluding retinal therapeutics.
Full Prescribing Information | Contact Us | Site Map | Privacy Policy | Allergan.com

©2011 Allergan, Inc., Irvine, CA 92612  All rights reserved.  ® marks owned by Allergan, Inc. www.allergan.com  APC18AT11  106848
This website is intended for US residents. Please visit the Allergan website for your country of residence for information concerning Allergan products and services available there.